Clinical trials
Relapsed Cancer clinical trials
Below are recruiting relapsed cancer clinical trials, each written for real people, not researchers. We’re tracking 162 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05022914Recruiting
PSMA PET/CT scan for PSA relapse after prostate surgery
This trial looks at using a PSMA PET/CT scan to better re-check cancer activity in men whose PSA has started rising after prostate removal. If you qualify, the scan may help doctors choose the next best treatment step.
FlorenceAges 18 years+ - NCT06644183RecruitingPhase 1/Phase 2
Triple therapy for relapsed CLL after prior treatments
This trial tests three drugs—roginolisib, venetoclax, and rituximab—for people with CLL that has come back or not responded after at least two prior treatments, including a BTK inhibitor. The goal is to see if this combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06681220RecruitingPhase 1/Phase 2
Temozolomide and stenoparib for relapsed small cell lung cancer
This trial tests two drugs—temozolomide and stenoparib—for people with small cell lung cancer that has returned after initial chemo. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Palo Alto, CaliforniaAges 18 years+ - NCT06888921RecruitingPhase 1/Phase 2
COM701 for platinum-sensitive ovarian cancer
This study tests a new drug, COM701, for people with ovarian cancer that came back after treatment but still responds to platinum-based chemotherapy. It aims to see if COM701 is safe and effective for patients who have already tried several treatments.
Augusta, GeorgiaAges 18 years+ - NCT07330544RecruitingPhase 2
Study of entinostat with anlotinib or fulvestrant for advanced breast cancer
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
Zhejiang, HangzhouAges 18 years+ - NCT04050345Recruiting
Blood test to spot DNA changes after early colon cancer surgery
This study checks a “cell-free tumor DNA” blood test to see if cancer mutations can predict relapse after surgery for early colorectal cancer. If results look risky, they may help guide closer follow-up and future treatment decisions.
Milton Keynes, BuckinghamshireAges 18 years+ - NCT06496048RecruitingPhase 3
Testing lurbinectedin for small cell lung cancer that has returned
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
Jilin CityAges 18 years+ - NCT05512364RecruitingPhase 3
Elacestrant for ER-positive, HER2-negative breast cancer with ctDNA relapse
This trial tests whether elacestrant can help stop or delay breast cancer coming back in people whose blood test shows “ctDNA relapse” after early breast cancer treatment. It’s meant for hormone receptor–positive, HER2-negative breast cancer patients who are already taking hormone (endocrine) therapy and have no visible spread on scans.
AnderlechtAges 18 years+ - NCT07416188RecruitingPhase 1/Phase 2
LMP744 drug for returning glioblastoma
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
Bethesda, MarylandAges 18–99 - NCT07180693Recruiting
Breast cancer that returns after CDK4/6 inhibitor treatment
This study looks at patients whose breast cancer returns after starting a CDK4/6 inhibitor (like abemaciclib or ribociclib) along with hormone therapy. The goal is to understand why the cancer comes back and find better ways to treat it.
Bergamo, ItalyAges 18 years+ - NCT05922501RecruitingPhase 2
Test four medicines for relapsed multiple myeloma
This Phase 2 study tests a combination of medicines (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) for multiple myeloma that has come back or did not respond to prior treatment. It may help by better controlling the myeloma after standard therapies have failed.
Boston, MassachusettsAges 18 years+ - NCT05704621RecruitingPhase 2
Surgery after PARP inhibitor failure in returning ovarian cancer
This trial tests whether doing additional (“secondary”) tumor-removal surgery can help people with ovarian, fallopian tube, or primary peritoneal cancer that has returned after PARP inhibitor maintenance. It focuses on people whose cancer can likely be fully removed and who are considered good candidates for surgery and follow-up treatment.
SeoulAges 18 years+ - NCT05732974Recruiting
Using a computer tool to find lung cancer relapse risk
This study uses a machine-learning computer method to identify people with early-stage lung cancer who have a higher risk of the cancer coming back after surgery. If you qualify, your information may help researchers improve how doctors predict relapse and plan follow-up care.
ToulouseAges 18 years+ - NCT05861505RecruitingPhase 3
Treatment for new liver spread from colon cancer recurrence
This Phase 3 trial studies a treatment approach for people whose colorectal cancer has come back in the liver within 12 months and can be treated with local procedures. It aims to see whether the study treatment can improve outcomes compared with standard care for people with a limited number of liver tumors.
AmsterdamAges 18 years+ - NCT04518501RecruitingPhase 1/Phase 2
Testing fuzuloparib with arsenic and platinum for ovarian cancer
This early-phase study tests a combination of three medicines to treat ovarian, fallopian tube, or primary peritoneal cancer that has come back after platinum chemotherapy, especially when tumors have a BRCA1 or BRCA2 mutation. The goal is to see if this treatment can help control cancer that is hard to treat.
Zhejiang, HangzhouAges 18–70 - NCT06643585RecruitingPhase 3
Comparing T-DXd to standard therapy for molecular relapse in early breast cancer
This trial compares a new drug called Trastuzumab-Deruxtecan (T-DXd) to standard treatment for people with early breast cancer whose cancer has come back at a molecular level (detected by a blood test) but hasn't spread to other parts of the body. The goal is to see if T-DXd can prevent the cancer from returning.
UlmAges 18–75 - NCT06203210RecruitingPhase 3
Study of a new drug for relapsed small cell lung cancer
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
Springdale, ArkansasAges 18 years+ - NCT06931626RecruitingPhase 1
Study of NMS-03305293 for relapsed small cell lung cancer
This trial tests a new drug, NMS-03305293, in adults with small cell lung cancer that has come back after earlier treatments. The goal is to see if it can help shrink or slow the cancer.
Peoria, IllinoisAges 18 years+ - NCT06498479RecruitingPhase 3
Comparing a new drug to topotecan for relapsed small cell lung cancer
This trial tests a new drug called HS-20093 against a standard drug (topotecan) for people with small cell lung cancer that has returned after initial treatment. The goal is to see which drug works better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06954246RecruitingPhase 3
New drug vs. doctor’s choice for relapsed small cell lung cancer
This trial tests a new drug called MHB088C for people with small cell lung cancer that has come back or gotten worse after standard treatments. It compares this drug to other options your doctor might choose. The goal is to see if MHB088C works better.
ShanghaiAges 18 years+ - NCT05450965RecruitingPhase 2
Onvansertib for relapsed small cell lung cancer
This trial studies onvansertib, a targeted medicine, in people whose small cell lung cancer has come back or did not respond to prior platinum chemotherapy. It aims to shrink tumors and improve outcomes after standard treatment has already been tried.
Baltimore, MarylandAges 18 years+ - NCT07189455RecruitingPhase 3
Comparing ZG006 to chemotherapy for relapsed small cell lung cancer
This study compares a new drug called ZG006 against standard chemotherapy for people with small cell lung cancer that has come back after prior treatment. The goal is to see if ZG006 works better or has fewer side effects.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05682131RecruitingPhase 4
Study for children with certain relapsed leukemia
This trial looks at treatment for children whose leukemia has come back for the first time. It focuses on a specific type of leukemia and risk level to see whether the approach improves outcomes.
Guangzhou, GuangdongAges 1–14 - NCT07218146RecruitingPhase 3
Study of ZL-1310 vs Standard Care for Relapsed Small Cell Lung Cancer
This trial tests a new drug, ZL-1310, against standard treatments for people with small cell lung cancer that has returned after initial therapy. The goal is to see if ZL-1310 works better than other options.
La Jolla, CaliforniaAges 18 years+
Hear when a new Relapsed Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed cancer?
- Yes. Clin2 currently lists 162 recruiting relapsed cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.